Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KCNJ1 | P48048 | 15/20 | 0.69 |
| ▸ | KCNH2 | Q12809 | 14/20 | 0.69 |
| ▸ | HRH3 | Q9Y5N1 | 3/20 | 0.65 |
| ▸ | MAOA | P21397 | 1/20 | 0.57 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.56 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14569972 | 0.87 | KCNJ1 (0.51) | KCNJ1KCNH2HRH3MAOASIGMAR1 | |
| SCHEMBL6738792 | 0.84 | KCNJ1 (0.50) | KCNJ1KCNH2HRH3MAOASIGMAR1 | |
| SCHEMBL2731306 | 0.82 | KCNJ1 (1.00) | KCNJ1KCNH2HRH3MAOASIGMAR1 | |
| SCHEMBL14569975 | 0.81 | KCNJ1 (0.46) | KCNJ1KCNH2HRH3MAOASIGMAR1 | |
| SCHEMBL10232396 | 0.81 | KCNJ1 (0.63) | KCNJ1KCNH2HRH3MAOASIGMAR1 | |
| SCHEMBL5653299 | 0.79 | HRH3 (0.93) | KCNJ1KCNH2HRH3MAOASIGMAR1 | |
| SCHEMBL3156895 | 0.79 | HRH3 (1.00) | KCNJ1KCNH2HRH3MAOASIGMAR1 | |
| SCHEMBL2723701 | 0.78 | KCNJ1 (0.59) | KCNJ1KCNH2HRH3MAOASIGMAR1 | |
| SCHEMBL10234046 | 0.78 | KCNJ1 (0.59) | KCNJ1KCNH2HRH3MAOASIGMAR1 | |
| SCHEMBL15215142 | 0.78 | KCNJ1 (0.59) | KCNJ1KCNH2HRH3MAOASIGMAR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1678499-B1 | CHEMICAL COMPOUND AND ASSAY | ASTRAZENECA AB (SE) | 2008-06-25 | — | — | EP | claimed |
| US-20070048215-A1 | Chemical compound and assay | ASTRAZENECA AB (SE) | 2007-03-01 | — | — | US | claimed |
| EP-1678499-A2 | CHEMICAL COMPOUND AND ASSAY | AstraZeneca AB (SE) | 2006-07-12 | — | — | EP | claimed |
| WO-2005037052-A2 | BINDING ASSAY WITH LABELLED BISPIDINE VARIANT | ASTRAZENECA AB (SE) | 2005-04-28 | — | — | WO | claimed |
| EP-1678499-B1 | CHEMICAL COMPOUND AND ASSAY | ASTRAZENECA AB (SE) | 2008-06-25 | — | — | EP | disclosed |
| US-20070048215-A1 | Chemical compound and assay | ASTRAZENECA AB (SE) | 2007-03-01 | — | — | US | disclosed |
| US-20070048215-A1 | Chemical compound and assay | ASTRAZENECA AB (SE) | 2007-03-01 | — | — | US | disclosed |
| US-20070048215-A1 | Chemical compound and assay | ASTRAZENECA AB (SE) | 2007-03-01 | — | — | US | disclosed |
| EP-1678499-A2 | CHEMICAL COMPOUND AND ASSAY | AstraZeneca AB (SE) | 2006-07-12 | — | — | EP | disclosed |
| WO-2005037052-A2 | BINDING ASSAY WITH LABELLED BISPIDINE VARIANT | ASTRAZENECA AB (SE) | 2005-04-28 | — | — | WO | disclosed |
| US-20030212095-A1 | New bispidine compounds and their use in the treatment of cardiac arrhythmias | ASTRAZENECA AB (SE) | 2003-11-13 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070048215-A1 | Chemical compound and assay | KCNH2, KCNH3, KCNJ5 | KCNJ1 18/4885KCNH2 1/4885HRH3 775/4885 |
| US-20030212095-A1 | New bispidine compounds and their use in the treatment of cardiac arrhythmias | KCNH1, LBR, CACNA1E | KCNJ1 129/4885KCNH2 7/4885HRH3 402/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.